Aktis Oncology Reports Q3 Revenue Growth and Significant Increase in Cash Reserves
Aktis Oncology (AKTS) reported third-quarter revenue of $3.91 million, representing a 147.5% increase year-over-year. This figure exceeded market expectations by $1.46 million, signaling strong top-line momentum for the company. The company also reported a substantial rise in its liquidity position. As of September 30, 2026, cash, cash equivalents, and marketable securities totaled $492.9 million, more than doubling the $226.8 million reported at the end of December 2025. This capital increase is attributed to net proceeds from recent financing activities.
Tickers: $AKTS